Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Unknown 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Gynecologic 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × TQ-B3525 × Lymphoid × Clear all
NCT04610970 2021-08-18

A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
93 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04615468 2020-11-04

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma(PTCL)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
78 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04398953 2020-09-11

A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
102 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT04324879 2020-07-01

A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
80 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡